Table 1.

Comparison of Brexpiprazole and Aripiprazole⁸,¹²

	Brexpiprazole	Aripiprazole
FDA-approved indications	Schizophrenia Adjunctive for major depressive disorder	Acute agitation Schizophrenia Bipolar I disorder (acute mania or mixed episode) Adjunctive for major depressive disorder
Predominant receptor binding	5-HT1A, D2, D3 partial agonist and 5-HT2A, 5-HT2B, 5-HT7, alpha1A, alpha1B, alpha1D, and alpha2C antagonist	D2 and 5-HT1A partial agonist and 5-HT2A antagonist
Predominant metabolism	CYP2D6 and CYP3A4	CYP2D6 and CYP3A4
Adverse events	Akathisia, weight gain, constipation, fatigue, somnolence, headache, tremor, dizziness, dyspepsia, and extrapyramidal symptoms	Akathisia, headache, weight gain, sedation, somnolence, dizziness, tremor, and extrapyramidal symptoms